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Background: Self-stigma has been highlighted and researched in relation to patients with chronic illnesses, as it
may have a negative impact on their treatment adherence. However, self-stigma has not yet been investigated in
patients with type 2 diabetes. In order to evaluate the extent to which patients with type 2 diabetes experience
self-stigma, which may result in their poor self-care management, there is a need for a specific tool to measure
self-stigma in patients with type 2 diabetes. This study assessed the psychometric properties of a Japanese version
of the Self-Stigma Scale (SSS-J) in patients with type 2 diabetes.
Methods: The reliability and validity of the SSS-J were evaluated using a consecutive sample of 210 outpatients
with type 2 diabetes from university hospitals and from hospitals or clinics specializing in diabetes treatment.
Confirmatory factor analysis was conducted to assess the factors theorized by the original Self-Stigma Scale.
Cronbach’s alpha for internal reliability and Pearson’s correlations for construct validity were used for evaluation
of psychometric properties. Pearson’s correlations for test-retest reliability of the SSS-J were also performed.
Results: Confirmatory factor analysis verified the three-factor structure of the SSS-J, consisting of cognitive, affective,
and behavioral subscales. The model fit indices were as follows: the goodness-of-fit index was 0.78, the adjusted
goodness-of-fit index was 0.70, the comparative fit index was 0.88, and the root mean square error of approximation was
0.07. Cronbach’s alpha of the SSS-J was 0.96 (cognitive: alpha = 0.92; affective: alpha = 0.93; behavioral: alpha = 0.83). The
SSS-J was associated with self-esteem (r = −0.43, p < 0.01), self-efficacy (r = −0.38, p < 0.01), and depressive symptoms
(r = 0.39, p < 0.01). The 2-week test-retest reliability demonstrated satisfactory stability (r = 0.76, p < 0.01).
Conclusions: The SSS-J is reliable and valid for assessment of the extent of self-stigma in Japanese patients with
type 2 diabetes.
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Self-stigma is experienced by individuals who have negative
attitudes towards themselves as a result of their condition
and/or characteristics [1,2]. Self-stigma is also referred to
as internalized stigma. Conversely, public stigma represents
negative reactions of the general public towards a group
based on stereotypical attributes that distinguish that group
in society [1,2]. Public stigma is also known as social
stigma. Self-stigma has a negative impact on individuals,* Correspondence: asukakato-tky@umin.ac.jp
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unless otherwise stated.resulting in decreased self-esteem, self-efficacy, life
satisfaction, social adaptation, overall well-being, and
social networking [1,3-7]. Additionally, this may lead to
either treatment avoidance or diminished treatment
adherence in patients with chronic illnesses [4,8,9].
Chronic illness, in particular type 2 diabetes, requires
a considerable amount of self-management by patients
in their everyday lives. Additionally, type 2 diabetes is
one of the most common chronic illnesses, and its
prevalence has dramatically increased worldwide in the
past two decades [10]. Likewise, the prevalence of type
2 diabetes in Japan has been on the rise [11]. As the
number of patients with type 2 diabetes increases, someis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Kato et al. Health and Quality of Life Outcomes  (2014) 12:179 Page 2 of 9preconceived ideas about their particular characteristics
result in blame being placed on them, because their
condition is considered to be a lifestyle-related disease.
People with type 2 diabetes are often subject to stigma-
tizing attitudes from the general population. Recently,
public stigma has been highlighted and researched in
relation to type 2 diabetes. According to these studies,
public stigma has a negative impact on diabetes self-
care management [12-15]. However, previous studies
have shown that merely perceiving public stigma does
not necessarily lead to self-stigma [1,2]. Self-stigma is
the issue that will impact patients’ behavioral goals
through decreased self-esteem, self-efficacy, and psycho-
logical well-being [1,4,7,9]. As a result, patients become
reluctant to seek necessary treatment and there is a reduced
treatment adherence [4,8,9]. Therefore, it is extremely
important to assess the extent to which patients experi-
ence self-stigma, so that early medical interventions for
self-esteem and self-efficacy can be provided to avoid sub-
optimal treatment outcomes. Nevertheless, there has not
yet been a study on self-stigma in patients with type 2
diabetes and how self-stigma could potentially have an im-
pact on their treatment outcomes.
To assess the extent to which patients with type 2 dia-
betes experience self-stigma, there is a need for a validated
tool to measure this construct. Although a number of vali-
dated tools for self-stigma have been developed, most have
only focused on mental disorders [16-19]. The Self-Stigma
Scale was originally developed to quantify and evaluate
concealed self-stigma among various groups of minorities,
such as immigrants and sexual minorities, as well as mental
health patients [20]. Type 2 diabetes is one of the condi-
tions that cannot be detected by looking at patients’ phys-
ical appearance. Therefore, patients with type 2 diabetes
can hide their stigmatized condition from the mainstream
of healthy individuals, although they do so with fear of be-
ing discovered [14,15]. For this reason, the Self-Stigma
Scale is viewed as the best tool that can be easily adapted
for use with the particularly concealable condition of type 2
diabetes. In this study, we translated the Self-Stigma Scale
from English to Japanese and examined its reliability and
validity in patients with type 2 diabetes. Furthermore, we
tested the equivalency between the Self-Stigma Scale (here-
after defined as “the original scale”) and the Japanese ver-
sion (SSS-J) when assessing patients with type 2 diabetes.
Methods
Development of the SSS-J
Translation procedures were based on the Consensus-
based Standards for the Selection of Health Measurement
Instruments checklist [21]. Four steps were followed
(Figure 1). Multiple forward and backward translations
were performed by six translators. They were selected
according to the following criteria:1. There were two forward translators who were both
native Japanese speakers. One translator had
expertise on stigma, and the other was a language
expert but lacked knowledge about stigma.
2. There were four backward translators. Two were
native English speakers, and the other two were
native Japanese speakers. They were all language
experts with no knowledge of stigma or the
original scale.
In Step 1, two native Japanese speakers worked inde-
pendently and translated the original scale into Japanese.
They were fully informed about the objectives of the
whole translation procedure, and forward translated all
the questionnaire items, not word-for-word but with
emphasis on the meaning of each item. We then com-
bined these two Japanese translations into one. To amal-
gamate these Japanese translations, the two translators
and three authors had discussions to reach a consensus
in terms of the following four criteria: content, seman-
tics, conceptualization, and technical equivalence with
the original scale, as well as cultural adaptations. In Step
2, another two native Japanese speakers worked independ-
ently and were asked to backward translate the Japanese
translation in Step 1 into English. We then combined
these two English translations into one by reaching a con-
sensus with the two translators in the same way as in Step
1. Afterwards, two bilingual individuals, whose native lan-
guage was English, checked for any semantic discrepancies
between the Japanese translation in Step 1 and the back-
ward translation in Step 2. All these backward translators
were blinded to the original scale. In Step 3, the English
translation produced in Step 2 was reviewed by the original
scale developers. Based on suggestions from them, some
questionnaire items were revised through repeated forward
and backward translation procedures (Steps 1 and 2) to
reflect the original meaning after translation.
In Step 4, the translation was pretested in cognitive
interviews by five outpatients with type 2 diabetes to
ensure accessibility and comprehension. They were men
and women aged 30–74 years with different educational
backgrounds ranging from those without a high school
education to those with a bachelor’s degree. According
to their comprehension level of the Japanese translation,
some words were altered to even plainer language. Add-
itionally, Japanese patients with type 2 diabetes did not
understand the direct translation of the term “identity”.
Therefore, with permission of the original scale devel-
opers, we replaced the term with a Japanese phrase,
“oneself with the illness, diabetes”, while maintaining the
conceptual equivalence in the original scale. Thereafter,
we processed Steps 2 and 3 in the same way. Finally, we
obtained permission from the original scale developers
to field test the revised translation.
Figure 1 Flow chart describing the development of the Japanese version of the Self-Stigma Scale. SSS: Self-Stigma Scale.
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The SSS-J was tested between November 2013 and March
2014. Consecutive sampling was used to recruit all outpa-
tients with type 2 diabetes who visited a diabetologist on a
specific date at four locations, comprising two university
hospitals (The University of Tokyo Hospital and Teikyo
University Hospital), one non-university affiliated hospital
(Mitsui Memorial Hospital), and one non-university affili-
ated clinic (The Institute for Adult Diseases Asahi Life
Foundation) in Japan. The following patients were ex-
cluded: non-native Japanese speakers; those aged 75 years
or older; and those with a serious mental disorder, such as
dementia, that affected their cognition. Additionally, pa-
tients who required urgent medical procedures or exami-
nations were excluded.
During enrollment, the purpose of the study was ex-
plained by study staff, and informed consent was obtained
from those who agreed to the terms of the study. The SSS-
J was self-administered in the majority of the participants.
For those who had either visual loss or poor literacy skills,
an audiotape was provided to read out each question. To
determine the test-retest reliability, all participants took
home another SSS-J questionnaire to complete after
2 weeks and this was mailed back to our office. Reminder
phone calls were made up to two times as necessary.
The sample size was calculated based on the number re-
quired to perform the factor analysis for the psychometric
assessment of the scale. Because it had 39 items, the
minimal sample size was 195 based on a participant-to-
item ratio of 5:1 [22].
This study was approved in advance by the Research
Ethics Committee of The University of Tokyo Graduate
School of Medicine and Faculty of Medicine.
Measures
A self-administered questionnaire was used to assess
diabetes-related complications and hemoglobin A1c. Thenumber of complications was calculated with reference to
the Diabetes Complications Index (DCI) [23]. The score
ranged from 0 to 6. Participants were asked to fill out their
hemoglobin A1c levels based on a copy of laboratory
results received that day.
SSS-J scale
The SSS-J comprises 39 items that allow four responses
in a Likert scale: strongly disagree, disagree, agree, and
strongly agree. The responses are afforded a score of 0,
1, 2, and 3, respectively. The total possible scores have a
range of 0–117. A higher score represents a higher level
of self-stigma.
We predicted that the SSS-J would be negatively associ-
ated with several self-identity measures, such as self-
esteem and self-efficacy, and that it would also be related
to greater levels of depressive symptoms. Our predictions
in a Japanese sample of patients with type 2 diabetes were
informed by the results of a previous study [20]. For com-
parison, participants completed the following measures in
addition to the SSS-J.
Self-esteem
The Rosenberg Self-Esteem Scale was used to assess the
level of self-esteem [24,25]. It is a widely accepted scale
because of its high reliability and validity. It contains 10
items scored on a 4-point Likert scale from 1 (strongly
disagree) to 4 (strongly agree). Five negative items were
reverse-scored to compute the total scores of individual
participants. In this study, it had an internal consistency
of 0.79.
Self-efficacy
The General Self-Efficacy Scale was applied to assess in-
dividual strength in general self-efficacy across a variety
of settings in everyday life [26]. It is reliable and valid,
and is commonly used to measure self-efficacy in Japan.
Table 1 Sociodemographic and clinical characteristics of
participants (n = 210)









Full-time work 121 (57.7)
Part-time work 50 (23.8)
Retired/not working 36 (17.1)
Others 3 (1.4)
Highest education:
Have not graduated high school 16 (7.6)
High school 66 (31.4)
Technical/junior college 34 (16.2)
Bachelor’s degree or higher 94 (44.8)
Duration of diabetes (years): 13.3 (± 9.6)
Primary treatment:
Oral hypoglycemic agents 123 (58.6)
Insulin injections 15 (7.1)
Insulin injections and oral hypoglycemic agents 45 (21.4)
Other injectable medications (other than insulin) 14 (6.7)
Lifestyle 13 (6.2)
HbA1c (%): 7.3 (± 1.2)






SD: standard deviation; HbA1c: glycated hemoglobin.
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In this study, it had an internal consistency of 0.84.
Depressive symptoms
The nine-item depression module of the Patient Health
Questionnaire (PHQ-9) was used to assess depressive
symptoms during the previous 2 weeks [27,28]. It is a reli-
able and valid measure of depression severity for clinical
use. Each item is scored on DSM-IV (Diagnostic and
Statistical Manual of Mental Disorders-IV) criteria from 0
(not at all) to 3 (nearly every day). In this study, it had an
internal consistency of 0.86.
Statistical analysis
The mean and standard deviation of each item of the
SSS-J were determined. Cronbach’s coefficient alpha was
calculated to assess the internal reliability of each sub-
scale defined by the original scale. Confirmatory factor
analysis was conducted on the SSS-J to confirm that the
three-factor model theorized in the original scale would
achieve the best fit for the data in Japanese patients with
type 2 diabetes. Model fitness was assessed based on the
maximum likelihood method by using the following fit
indices: goodness-of-fit index (GFI), adjusted goodness-
of-fit index (AGFI), comparative fit index (CFI), and root
mean square error of approximation (RMSEA). The
model was built using three self-stigma subscales, which
consisted of 19 cognitive, 14 affective, and six behavioral
items as observed variables. The construct validity was
examined with Pearson’s correlations in the Self-Esteem,
General Self-Efficacy, and PHQ-9 scales.
All analyses were conducted with SPSS version 18.0
(SPSS Japan Inc., Tokyo, Japan), except for the confirma-
tory factor analysis, which was performed using AMOS
version 18.0 (SPSS Japan Inc., Tokyo, Japan).
Results
Physicians recruited 259 patients with type 2 diabetes
and written informed consent was obtained from 218,
giving a response rate of 84.2%. Of these patients, 217
completed the questionnaire (one patient declined). The
percentage of missing data was zero for all questionnaire
items. In the analysis, we excluded five participants who
answered all 39 items of the SSS-J with a “strongly
disagree” response, because they responded strongly to
stigma, and we did not know whether the scale could
measure what it was originally intended to assess. We
also excluded two participants who had vision loss and
completed the questionnaire with the aid of an audio-
tape, because they used different cognitive tasks from
those who were able to answer all of the questionnaire
items on their own. Therefore, 210 participants were
included in our final analysis. Of these remaining par-
ticipants, 187 answered and returned the secondquestionnaire containing the SSS-J items 2 weeks later,
producing a response rate of 89.0%.
Descriptive statistics for the SSS-J
The sociodemographic and clinical characteristics of the
participants are shown in Table 1. There were 169 male
participants (80.5%) and 41 female participants (19.5%),
and the mean age was 60.1 ± 10.0 years. The mean dur-
ation of type 2 diabetes was 13.3 ± 9.6 years and the mean
hemoglobin A1c level was 7.3 ± 1.2%. The number of
complications was calculated as the simple sum of the six
complications from the DCI [23]. The score range was 0–
6, and 62.4% of participants had no complications. Table 2
Table 2 Scores of items in the Japanese version of the Self-Stigma Scale in type 2 diabetes patients
M SD
COGNITIVE Being a ___ takes away many opportunities from me. (29) 1.85 0.67
I think that I am less competent than ordinary people because I am a ___. (26) 1.59 0.57
I feel that my life is unenjoyable because of myself with the illness, ___. (31) 1.81 0.69
No matter how hard I work, I cannot match others because of myself with the illness, ___. (30) 1.64 0.55
Who I am: having the illness, ___, is a heavy burden to me. (38) 2.17 0.78
I have low expectations in life because I am a ___. (18) 1.80 0.64
I am not qualified to compete with others because I am a ___. (27) 1.54 0.54
Who I am: having the illness, ___, is a stigma in my life. (13) 1.92 0.73
Who I am: having the illness, ___, has a negative impact on my financial situation. (35) 2.15 0.83
I am inferior to others because I am a ___. (21) 1.66 0.58
Who I am: having the illness, ___, causes inconvenience on my daily life. (34) 2.13 0.76
I cannot measure up to ordinary people because I am a ___. (10) 1.68 0.65
I cannot change myself with the illness, ___. (11) 1.90 0.67
I lower my standards of living because I am a ___. (6) 1.90 0.65
My life is meaningless because I am a ___. (4) 1.63 0.51
I need assistance from others because I am a ___. (12) 1.77 0.67
My social interactions are limited because I am a ___. (2) 2.04 0.66
It is quite normal for me to be alienated by others because I am a ___. (5) 1.55 0.51
I feel much stressed because I am a ___. (1) 2.49 0.73
AFFECTIVE I cannot feel confident about who I am because of myself with the illness, ___. (33) 1.74 0.61
I am worried about who I am: having the illness, ___, would create obstacles to me. (25) 1.90 0.74
I have negative feelings about myself with the illness, ___. (23) 1.79 0.68
I am unhappy because I am a ___. (32) 1.80 0.69
I feel helpless because I am a ___. (37) 1.59 0.57
I am discouraged because I am a ___. (28) 1.84 0.71
I hate myself because I am a ___. (24) 1.89 0.71
I get embarrassed because of myself with the illness, ___. (39) 1.68 0.68
I feel angry because I am a ___. (22) 1.96 0.75
I feel uncomfortable being a ___. (17) 2.22 0.80
I feel sorry that I am a ___. (8) 1.98 0.73
I feel there is nothing I can do about being a ___. (16) 1.92 0.74
I fear that people around me would find out that I am a ___. (15) 1.75 0.78
I am ashamed of being a ___. (3) 1.99 0.72
BEHAVIORAL I avoid interacting with others because I am a ___. (36) 1.55 0.56
I keep my distance from others because I am a ___. (19) 1.57 0.62
I give up on myself because I am a ___. (14) 1.69 0.63
I hide myself with the illness, ___. (20) 1.66 0.77
I make friends only with people who are in the same condition as mine. (9) 1.48 0.56
I dare not to make new friends because they might find out that I am a ___. (7) 1.53 0.58
____ in each question item was replaced by either “diabetes” or “patient with diabetes”. The numerical values in parentheses after each question item reflect the
order in which the items appeared as the patients completed the SSS-J. Questionnaire items within each subscale are listed in descending order of factor loading.
M: mean; SD: standard deviation; SSS-J: Self-Stigma Scale, Japanese version.
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of the SSS-J questionnaire. In the SSS-J, the mean scores
were lower and the standard deviations were smaller inour patients for all items compared with the scores for
mental health patients using the original scale. The score
distributions were not found to be highly skewed.
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The results of the confirmatory factor analysis are demon-
strated in Figure 2. All path coefficients were significant.
The model fit indices were as follows: GFI = 0.78, AGFI =
0.70, CFI = 0.88, and RMSEA= 0.07. The goodness-of-fit
indices for the confirmatory factor analysis were acceptable.
There was a relatively good fit between the three-factor















Figure 2 Results of the confirmatory factor analysis of the Japanese v
GFI: goodness-of-fit index; AGFI: adjusted GFI; CFI: comparative fit index; RMbelow 0.9. However, the GFI depends on the total number
of observed variables [29]. As the SSS-J was tested using 39
items, the GFI in this sample would be less than 0.9. How-
ever, all factor loadings based on the three-factor model of
the 39 items were higher than the general standard (0.4) in
this sample. Additionally, the CFI value of 0.88 is close to
0.90, indicating a relatively good fit [30]. The RMSEA value





















































































































ersion of the Self-Stigma Scale in patients with type 2 diabetes.
SEA: root mean square error of approximation.
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The internal consistency of the SSS-J was excellent: Cron-
bach’s alpha = 0.96. The internal consistency of each con-
ceptual dimension of the SSS-J ranged from acceptable to
excellent: cognitive (Cronbach’s alpha = 0.92), affective
(Cronbach’s alpha = 0.93), and behavioral (Cronbach’s
alpha = 0.83). This demonstrated excellent internal
consistency reliability, indicating adequate interrelations
between the items of the scale.
Test-retest reliability
Test-retest reliability was determined by comparing re-
sponses to the SSS-J among 187 participants (89.0%) who
completed the questionnaire at home after a 2-week interval.
The correlation coefficient for test-retest reliability was 0.76
(p < 0.01). This demonstrated acceptable reproducibility. A
correlation coefficient range of 0.7–0.8 is acceptable [32].
Construct validity
Significant Pearson’s correlations were observed when ana-
lyzing the scores in the SSS-J and the other comparable
scales. The Rosenberg Self-Esteem (r = −0.43, p < 0.01) and
the General Self-Efficacy (r = −0.38, p < 0.01) scales were
negatively correlated with the SSS-J, whereas the PHQ-9
demonstrated a positive correlation (r = 0.39, p < 0.01).
This was consistent with predictions based on the results
of the original scale.
For the participants in this study, the median self-stigma
score was 75 with a range of 40–109, and the median de-
pressive symptoms score was 3 with a range of 0–25.
Discussion
This is the first study to examine the reliability and validity
of the Japanese version of the Self-Stigma Scale to assess
the extent of self-stigma among individuals with type 2
diabetes. The SSS-J was developed based on several for-
ward and backward translations with cross-cultural valid-
ation. All the questionnaire items were comprehensible by
both elderly people and individuals with lower educational
levels. The SSS-J also offered reliable and valid determin-
ation of psychometric properties as well as the relevant
structure of self-stigma consisting of cognitive, affective,
and behavioral subscales in the same manner as the
original scale [20].
The results indicated that the SSS-J consistently con-
structed the three-factor model as in the original scale
while using a different focus group and language. Further-
more, they indicated that each subscale had adequate
internal consistency. This demonstrates that the SSS-J can
be used to assess self-stigma among Japanese people with
type 2 diabetes. It should be noted that among people with
type 2 diabetes, items with higher factor loadings differed
from those in the original scale (Table 2).In the SSS-J, the mean scores in all questionnaire items
were lower among patients with type 2 diabetes than in
the original scale that targeted minorities with concealed
self-stigma, such as mental health patients. As previous
studies have shown, it is speculated that those patients
who have a high educational attainment, whose conditions
are less severe, and whose treatment is sustained are less
likely to develop self-stigma [33-35]. Our sample consisted
of a higher percentage of these subgroups. However, we
cannot conclude anything definite about the possible
reasons for the low scores to explain the current data. Fur-
ther research is needed to determine whether patients
with type 2 diabetes do indeed have lower scores in terms
of self-stigma when compared with patients with other
chronic physical illnesses, as well as mental illnesses.
There are some limitations to this study. First, the par-
ticipating patients with type 2 diabetes were recruited
from specialist hospitals/clinics. Patients who were seen
regularly by a primary care doctor were not included, and
neither were those who were not treated after diagnosis.
Further research in a more representative population is
needed in the specialty field, and also in primary care set-
tings. Second, a sample with similar disease characteristics
as used in the original scale, i.e., patients with mental
disorders, was not tested. Further research using such a
sample is needed to assess the cross-cultural validity of
the SSS-J more precisely. Third, diabetes-related compli-
cations were self-reported by participants, and the data
were likely to be under-reported. To overcome the limita-
tion of this self-reported assessment, an alternative vari-
able, the duration of type 2 diabetes, was used to proxy for
the severity of the illness. Fourth, there was a sex imbal-
ance in our sample, as the percentage of men was 80.5%
and the percentage of women was 19.5%. Although the
prevalence of type 2 diabetes is higher among men
(15.3%) than women (7.3%) in Japan [11], it is not known
exactly why we had such a large number of male respon-
dents, compared with female respondents. Finally, we
were not able to assess the concurrent validity of self-
stigma, as no similar validated scale exists for comparison.
Although there are other generic stigma scales targeting
people with psychiatric disorders, they do not necessarily
assess the same construct as self-stigma for people with
chronic physical illnesses.
Nevertheless, use of this self-administered scale would
be valuable to assess the levels of self-stigma in individual
patients with type 2 diabetes in daily clinical practice. In a
chronic disease such as type 2 diabetes, patient self-care is
necessary and a validated tool of self-stigma would indi-
cate the need for measures to be taken to eliminate a pos-
sible barrier to optimal treatment. In psychiatric patients,
there is evidence that self-stigma reduction programs are
effective in improving their self-esteem, promoting their
readiness to change their own problematic behavior, and
Kato et al. Health and Quality of Life Outcomes  (2014) 12:179 Page 8 of 9facilitating their treatment adherence [36-38]. Similar ef-
fects may be expected in patients with type 2 diabetes,
with improved treatment adherence by lowering levels of
self-stigma through patient education programs.
Conclusions
This study has demonstrated that the SSS-J produces the
same factor structure as the original Self-Stigma Scale
through testing by confirmatory factor analysis. Further-
more, it indicated that the SSS-J could be a useful clinical
tool to help healthcare professionals identify high-risk
self-stigma patients with type 2 diabetes. For clinical use
of the SSS-J, given its length, a shorter version should be
developed as this will avoid some redundant items while
incorporating more relevant items. In addition, further
studies are needed to discover the optimum time during
the treatment process to respond to self-stigma in individ-
ual patients with type 2 diabetes, as well as the most ef-
fective places to assess the extent of self-stigma. With
continual use of the SSS-J, the degree of self-stigma may
be accurately assessed. As a result of these assessments, it
would be possible to provide patients with different treat-
ment strategies in addition to early intervention to help
reduce self-stigma. This could then lead to optimal treat-
ment outcomes.
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